Uroxatral: Targeted Relief for Benign Prostatic Hyperplasia Symptoms
Uroxatral
| Product dosage: 10mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | 2.03 $ | 60.84 $ 60.84 $ (0%) | 🛒 Add to cart |
| 60 | 1.66 $ | 121.68 $ 99.45 $ (18%) | 🛒 Add to cart |
| 90 | 1.53 $ | 182.52 $ 138.06 $ (24%) | 🛒 Add to cart |
| 120 | 1.40 $ | 243.36 $ 168.48 $ (31%) | 🛒 Add to cart |
| 180 | 1.29 $ | 365.04 $ 231.66 $ (37%) | 🛒 Add to cart |
| 270 | 1.17 $ | 547.56 $ 315.90 $ (42%) | 🛒 Add to cart |
| 360 | 1.05 $
Best per pill | 730.08 $ 379.08 $ (48%) | 🛒 Add to cart |
Synonyms | |||
Uroxatral (alfuzosin HCl) is a prescription medication specifically designed to manage the urinary symptoms associated with benign prostatic hyperplasia (BPH) in adult men. As an alpha-1 adrenergic receptor antagonist, it works by relaxing the smooth muscles of the prostate and bladder neck, facilitating improved urine flow and reducing obstructive and irritative voiding difficulties. Its selective action and once-daily dosing regimen offer a convenient and effective option for long-term symptom management, supported by extensive clinical evidence and a favorable safety profile when used as directed under medical supervision.
Features
- Contains alfuzosin hydrochloride as the active ingredient
- Available in 10 mg extended-release tablets
- Designed for once-daily oral administration
- Formulated with a unique gastroretentive delivery system for consistent absorption
- Requires no dose titration for most patients
- Manufactured under strict pharmaceutical quality standards
Benefits
- Significantly improves urinary flow rate and reduces hesitancy
- Decreases the frequency and urgency of urination, including nocturia
- Alleviates sensation of incomplete bladder emptying
- Enhances overall quality of life through sustained symptom relief
- Minimizes BPH-related discomfort and complications over time
- Supports uninterrupted daily activities and restful sleep patterns
Common use
Uroxatral is primarily indicated for the treatment of signs and symptoms of benign prostatic hyperplasia (BPH) in adult males. It addresses both obstructive symptoms (such as weak stream, straining, and terminal dribbling) and irritative symptoms (including urgency, frequency, and nocturia). It is not approved for use in women or pediatric populations and does not treat prostate cancer or prevent its development. Treatment is typically long-term, with symptomatic improvement often noticeable within weeks of initiation.
Dosage and direction
The recommended dosage of Uroxatral is one 10 mg extended-release tablet taken orally once daily, immediately after the same meal each day. Tablets must be swallowed whole and not crushed, chewed, or divided. Administration with food is essential to ensure proper absorption and maintain therapeutic drug levels. Dosage adjustment is generally not required for elderly patients or those with renal impairment, but caution is advised in hepatic impairment. Treatment should be initiated and monitored by a healthcare professional familiar with BPH management.
Precautions
Patients should be screened for prostate cancer before initiating and during therapy, as BPH symptoms may mimic malignancy. Use with caution in patients with severe renal impairment (CrCl <30 mL/min) or moderate to severe hepatic impairment. Orthostatic hypotension with or without symptoms (dizziness, lightheadedness) may occur, particularly within hours after initial doses or dosage increases. Patients should avoid situations where injury could result should syncope occur. Intraoperative floppy iris syndrome has been observed during cataract surgery in patients taking alpha-blockers; ophthalmologists should be informed prior to procedure.
Contraindications
Uroxatral is contraindicated in patients with known hypersensitivity to alfuzosin hydrochloride or any component of the formulation. Concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir) is contraindicated due to significantly increased alfuzosin exposure. Use is also contraindicated in patients with moderate to severe hepatic impairment (Child-Pugh categories B and C) due to altered metabolism. Should not be used in combination with other alpha-adrenergic blocking agents.
Possible side effect
Common adverse reactions (≥2%) include dizziness (6.3%), upper respiratory tract infection (3.2%), headache (3.2%), fatigue (3.0%), and abdominal pain/discomfort (1.8%). Postural hypotension reported in 0.4-1.3% of patients. Less frequent side effects may include palpitations, nausea, constipation, rash, impotence, priapism (rare but requires immediate medical attention), syncope (0.1-0.3%), and angioedema. Most side effects are mild to moderate and often diminish with continued therapy.
Drug interaction
Strong CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir) significantly increase alfuzosin exposure—concomitant use contraindicated. Other alpha-adrenergic blockers may potentiate hypotensive effects—concomitant use not recommended. Moderate CYP3A4 inhibitors (e.g., erythromycin, diltiazem) may increase alfuzosin levels—use with caution. Antihypertensives and phosphodiesterase-5 inhibitors may enhance hypotensive effects. No clinically significant interactions observed with atenolol, digoxin, or warfarin in clinical studies.
Missed dose
If a dose is missed, it should be taken as soon as remembered on the same day with food. If the day’s meal has already passed, skip the missed dose and resume the regular dosing schedule with the next meal the following day. Do not take two doses at the same time or extra tablets to make up for a missed dose. Maintaining consistent dosing with meals optimizes therapeutic efficacy and minimizes potential side effects.
Overdose
Expected manifestations would primarily relate to excessive alpha-adrenergic blockade, including significant hypotension, cardiovascular effects such as tachycardia, and possibly syncope. Supportive care should be initiated, including cardiovascular monitoring and appropriate measures to maintain blood pressure and heart rate. Dialysis is unlikely to be beneficial due to high protein binding. Symptomatic treatment for hypotension may include IV fluids and vasopressors if necessary. Patients should seek immediate medical attention if overdose is suspected.
Storage
Store at controlled room temperature 20°-25°C (68°-77°F); excursions permitted to 15°-30°C (59°-86°F). Keep in original container with lid tightly closed to protect from moisture and light. Keep out of reach of children and pets. Do not use beyond the expiration date printed on the packaging. Properly discard any unused or expired medication through medication take-back programs or according to local guidelines.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Uroxatral is a prescription medication that should be used only under the supervision of a qualified healthcare professional. Individual results may vary. Patients should consult their physician for proper diagnosis, treatment options, and monitoring. Never initiate or discontinue medication without professional medical guidance.
Reviews
Clinical studies demonstrate significant improvement in IPSS (International Prostate Symptom Score) with alfuzosin treatment, with mean reductions of 4.6-5.3 points versus placebo. Maximum urinary flow rate (Qmax) improvements of 1.7-2.3 mL/sec observed in controlled trials. Long-term extension studies show maintained efficacy over 2-3 years of treatment. Patient-reported outcomes indicate meaningful improvements in quality of life measures. Real-world evidence supports its tolerability and effectiveness in diverse clinical populations when used appropriately.